Home
About Us
Membership
Member Biography

Member Biography

Scott L. Coven, DO

Scott L. Coven, D.O.

Phone: (317) 944-8784

705 Riley Hospital Drive
ROC 4340
Indianapolis, IN 46202

Faculty appointments

Adjunct Assistant Professor, Community and Health Systems
Assistant Professor of Clinical Pediatrics, Department of Pediatrics, Division of Hematology/Oncology, IU School of Medicine
Associate member, Cancer Prevention and Control

Infectious Disease Outcomes in Pediatric Oncology Patients.PHO-IIR-INFECTIOUSDISEASE

Assessing Household Material Hardship in Children with Central Nervous System (CNS) Tumors.PHO-IIR-IUSCCC-0797

Assessing Fatigue Experienced by Pediatric Patients with Intracranial NeoplasmsPHO-IU-SHIH-FATIGUE

Distress during COVID-19 Pandemic for Caregivers of Children with Hematologic and Oncologic Diagnoses.PHO-IIR-COVID-19-DISTRESS

Books 4 Brains Book Club and Community Circle (15991 Sub-Study: Exploratory Aim).PHO-ILT-15991-SUB-STUDY

A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following RadiotherapyPHO-LILLY-I3Y-MC-JPEH

A Protocol for Children and Young Adults Diagnosed with a Central Nervous System (CNS) Tumor to Assess Cognitive, Quality of Life (QOL), and Comprehensive Effects of TherapiesPHO-UCSF-PNOC-COMP

Navigating Pediatric Hematology/Oncology Care Before and After the COVID-19 Era: Understanding the Influence of Social Determinants on Telehealth VisitsPHO-IIR-22701

RETROSPECTIVE ANALYSIS OF CLINICAL, IMAGING, HISTOMORPHOLOGIC AND MOLECULAR CHARACTERISTICS OF HIGH-RISK PEDIATRIC LOW-GRADE PRIMARY TUMORS OF THE CENTRAL NERVOUS SYSTEMPHO-STJUDE-CNS

Health Equity Community Engagement Through Family PartnershipsPHO-IIR-HECE

A Registry Study for Children with Atypical Teratoid Rhabdoid Tumor (ATRT)PHO-PNOC-PNOC030

A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of ProgressionPHO-UCSF-PNOC022

The Rare Brain Tumour Consortium Registry and BiobankPHO-SICKKIDS-BIOBANK-REGISTRY

An open label, multi-center roll-over study to assess longterm effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib).PHO-NOVARTIS-CDRB436G2401

Nivolumab and DAY101 for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adultsPHO-UCSF-PNOC029

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 study to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus SoC chemotherapy in patients with pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy.PHO-DOB-FIREFLY-2

Exploring the Pediatric Brain Cancer Diagnosis Experience (15991 Sub-Study: Aim 3)CTSI-IIR-15991-SUB-STUDY-AIM3

A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas and High Grade Gliomas PHO-PNOC-PNOC021

A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition followed by Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG).PHO-PNOC-PNOC019

A Phase I Study of Intra-Tumoral Injections of Ex Vivo Expanded Natural Killer Cells in Children and Young Adults With Recurrent or Progressive Supratentorial Malignant Brain TumorsPHO-UCSF-PNOC028

ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter StudyPHO-CHIMERIX-ONC201

NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS: CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WITH EITHER SINGLE CYCLE (LOW RISK PATIENTS) OR RANDOMIZATION (HIGH RISK PATIENTS) TO either SINGLE-CYCLE or TO THREE TANDEM CYCLES OF MARROW-ABLATIVE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUEPHO-SHIH-NWC-HEADSTART4

#ResearchCuresCancer

Support Our Research